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Introduction
Active transport mechanisms as determinants of drug absorption, distribution, and clearance have been the focus of considerable research effort over the past decade. Of the numerous transporter proteins recently investigated, the one for which the greatest amount of knowledge exists is Pglycoprotein (MDR1). Originally described as a transporter involved in imparting drug resistance to tumor cells, P-glycoprotein has been demonstrated to be important in reducing absorption of drugs from the intestinal lumen, in active secretion of drugs into urine and bile, and in extrusion of drugs from vital organs such as the brain and reproductive tissues (Troutman, et al., 2002) . As such, Pglycoprotein mediated transport has become an important issue in the discovery and development of new drugs. For example, new compounds that are promising with regard to target receptor/enzyme activity can be severely hampered in their ability to elicit pharmacological effects in vivo should they be good substrates for P-glycoprotein, especially if the route of administration is intended to be per oral or the target tissues is one rich in P-glycoprotein activity. Furthermore, the potential for drug-drug interactions arises in the event that the P-glycoprotein substrate is coadministered with another agent that can inhibit P-glycoprotein.
Several models have been developed to assess drugs as P-glycoprotein substrates. In vitro models have included the Caco-2 cell line which expresses this transporter (among numerous others) and cell lines stably transfected with P-glycoprotein, such as Madin-Darby canine kidney cells (MDCK) . Such cell lines can be used with P-glycoprotein inhibitors or substrate transport can be studied in transfected vs control cells to measure P-glycoprotein activity. Additionally, animal models have also been used to assess the impact of P-glycoprotein on substrate pharmacokinetics and/or effect. Some specific breeds of dogs have been shown to lack functional P-glycoprotein and the effects of drugs that are P-glycoprotein substrates can be markedly different in such animals (e.g. ivermectin toxicity in collie dogs, Mealey, et al., 2003; Roulet, et al., 2003) . A very powerful tool has been developed by Schinkel and coworkers: the mdr1a/1b knockout mouse model (Schinkel, et al., 1996) . These are genetically modified animals in which both genes that are homologous to the human MDR1 gene have been disrupted, resulting in a viable line of animals. These animals have seen widespread use in investigating the function of P-glycoprotein in drug disposition. Additionally, a DMD#1230 variant subpopulation of CF-1 mice lacking functional mdr1a has been identified and characterized (Umbenhauer, et al., 1997) and used in studies to address the role of this transporter in drug disposition (Kwei, et al., 1999; Yamazaki, et al., 2001 ).
In our ongoing efforts to identify new agents for disorders of the central nervous system, we have frequently applied the mdr1a/1b knockout mouse model. Comparison of the B/P AUC ratio in knockout animals vs wild-type animals has become a standard experimental approach to determine whether P-glycoprotein mediated efflux poses a potential threat to the activity of CNS agents in vivo, or a confounding factor in attempts to relate circulating free drug concentrations to effect in animal pharmacology models. Such in vivo data can be used in concert with data obtained using in vitro models, to assess the potential liability of P-glycoprotein mediated efflux from the brain.
However, it has been a common observation of ours that the conclusion for various compounds from in vitro P-glycoprotein data have not been consistent with the data we have obtained in the mdr1a/1b knockout mouse model. When discord has been observed, it has been that the in vivo mouse model has suggested that P-glycoprotein is an important determinant in the CNS penetration of the compound while the in vitro data has supported the opposite conclusion. A variety of factors could be responsible for such disagreement including interspecies differences in intrinsic activity of Pglycoprotein (which are not identical between human and mouse and could have different expression levels at the blood-brain barrier between the species) or failure of the in vitro models to demonstrate adequate representation of P-glycoprotein activity relative to other phenomena, such as passive diffusion rates, that can occur in vitro.
Because of these uncertainties, we have undertaken a large study in which we have examined over thirty well-established CNS agents of a variety of chemical and therapeutic classes in the mdr1a/1b knockout mouse model. Additionally, several non-CNS agents, some known to be Pglycoprotein substrates, were assessed in this model for comparison. The objective of this study was to determine how CNS-active agents, as a group, behave in the mdr1a/1b knockout mouse model with regard to brain-plasma pharmacokinetics. The following questions were kept in mind in pursuing this objective: (1) Are there CNS-active agents that demonstrate a large difference in B/P ratio in knockout vs wild-type mice? (2) Is the ratio of B/P AUC ratios between knockout and wild-type typically unity for
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Materials and Methods
Chemicals. Supplies of cyclobenzaprine, fluoxetine, methylphenidate, prazosin, and sertraline were obtained from Pfizer Global Material Management (Groton, CT). Citalopram, paroxetine, ritonavir and loratadine were purchased from Sequoia Research Products (Oxford, United Kingdom). The following reagents were purchased from the respective vendors: amiodarone (Spectrum Chemical, Gardenia, CA), clozapine (ICN Biochemicals, Irvine, CA), fluvoxamine (Tocris Cookson, Ellisville, MO), 9-hydroxyrisperidone (Synfine, Richmond, OR), midazolam (Cerilliant, Round Rock, TX), propoxyphene (US Pharamcopoeia, Rockville, MD), and venlafaxine (Alchemie USA, Plantsville, CT). All other drugs included in the study were purchased from Sigma-Aldrich (St. Louis, MO).
Animals.
Female FVB (wild-type) and mdr1a/1b (-/-, -/-) mice of approximately 9 weeks of age, weighing 25-30 grams, were obtained from Taconic Labs (Germantown, NY). For quinidine, loperamide, and caffeine, male FVB (wild-type) and mdr1a (-/-) mice were used. Upon arrival, the mice were maintained for at least 5 days on a 12 hr light/dark cycle in a temperature and humidity controlled environment with free access to food and water. The mice were housed in clear polycarbonate boxes (N=5 per box) containing sawdust and nesting pads. The study was conducted in accordance with approved Pfizer Animal Care and Use Procedures.
Drug Selection. The process of drug selection for the study was approached with the objective of identifying a representative and diverse sampling of the most commonly used CNS therapeutic agents.
To identify the top selling CNS drugs, a market assessment was conducted for total dollar sales and number of worldwide and US prescriptions filled for the year 2001. To ensure chemical diversity of the data set, a structure cluster analysis was conducted. The UNITY fingerprints of CNS drugs were calculated using the software package SYBYL ® 6.7.1 (Tripos Inc, St. Louis, MO.) and then grouped based on a hierarchical clustering algorithm. Drugs for the study were then selected based on a combination of factors including availability, market prevalence, pharmacology, chemical structure (based on clustering algorithm) and analytical feasibility.
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The exercise resulted in the identification of 32 CNS drugs representing 31 distinct structure clusters. In addition, the active metabolites of risperidone and carisoprodol (9-hydroxyrisperidone and meprobamate, respectively) were added to the study to evaluate the potential contribution of any metabolite interactions with P-gp on the biological activity of parent drug. Excluded from consideration as CNS agents were the anti-inflammatory drugs indicated for pain, and anti-migraine agents due to the peripheral location of their targeted receptors and because of the potential for disruption of the blood-brain barrier during migraine episodes (Goadsby, 2000) . A smaller set of 8 non-CNS drugs were selected for evaluation in the study as controls. The drugs were selected for their consideration as P-gp modulators, though not necessarily as substrates for transport, and to represent a range in the degree of interaction spanning from weak or moderate to strong. Included as positive controls for substrates transported by P-gp were: quinidine, an antiarrhythmic agent,; lopermide, an antidiarrheal; verapamil, an antihypertensive calcium channel blocker; loratadine, a non-sedating antihistamine; and ritonavir, an HIV protease inhibitor. The antiarrhythmic agent, amiodarone, was selected as a known P-gp inhibitor of very high lipophilicity.
Also included were prazosin, the antihypertensive agent commonly used for photoaffinity labeling of the drug-binding site on P-gp and prednisone, a glucocorticoid. hydroxypropyl β-cyclodextrin, such that doses were administered in a volume of 10 mL/kg. Dosing solutions were quinidine (10 mg/kg), loperamide (1 mg/kg), and caffeine (5 mg/kg). Mice were euthanized in a CO 2 chamber at 0.5, 1, 2.5, or 5 hours post-dose. Cerebrospinal fluid (CSF) was collected via puncture of the cisterna magna using a 25-gauge needle attached to polyethylene tubing (internal diameter of 2.0mm) and syringe. Whole blood was collected by cardiac puncture into Microtainer tubes containing heparin and stored on ice until centrifuged for the preparation of plasma. Whole brains were collected by decapitation, rinsed in phosphate buffered saline, and weighed. CSF and whole brains were immediately frozen on dry ice upon collection. Note that the data reported for 9-hydroxyrisperidone resulted from the separate and direct administration of the metabolite to FVB and mdr1a/1b mice whereas concentrations of meprobamate were determined as the metabolite formed following carisoprodol administration.
Analysis of Drugs in Mouse Plasma, Brain, and CSF. Plasma, CSF, and brain samples for all drugs were analyzed by HPLC-MS. Summaries of the analytical methods for plasma are available as Supplemental Information. In many cases, drugs were processed by liquid-liquid extraction, while others were subjected to solid phase extraction or deproteination using CH 3 CN. Brains were homogenized in four volumes of water, and homogenates were processed and analyzed in a similar fashion to plasma samples. CSF samples were analyzed using the same HPLC-MS conditions and were either directly injected on HPLC or were first evaporated and reconstituted in mobile phase before HPLC analysis. Settings and potentials for the mass spectrometers were adjusted to optimize the signal for each analyte. All samples were analyzed for concentrations of intact parent drug with the exception of meprobamate, which was monitored as a metabolite formed following administration of carisoprodol.
This article has not been copyedited and formatted. The final version may differ from this version. The AUCs were calculated using the trapezoid rule and the variances of the AUCs were determined from the weighted sum of the concentration variance at each time point. The weights were determined from the time separation weights found in the trapezoid rule. The AUC ratios, B/P, CSF/brain and CSF/plasma were calculated and the respective variances determined using the first order Taylor series expansion of the ratios. The correlation between brain, plasma and CSF concentrations were incorporated into the variance estimate.
The B/P, CSF/plasma, and CSF/brain ratios were then used to compare KO to WT ratios to determine a step-wise significant increase from 1, 2, 3 and 4 (although results for 3 and 4 were not different from 2 and are not reported). The KO/WT ratios were compared using a log transform of the ratios and an approximation to the variance. The comparisons of the log-transformed ratios were done using a t-test with unequal variances. All statistical calculations and analyses were completed using
SAS Version 8.0 (SAS Institute, Cary, NC).
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Thirty-two drugs (and two metabolites) were selected for evaluating differences in central exposures of CNS active agents using the mdr1a/1b double knockout mice model. Each drug was administered as a 3 mg/kg subcutaneous dose and concentrations were determined in plasma, brain, and CSF at 0.5, 1, 2.5, and 5 hours post-dose. The resulting AUC, Cmax, and Tmax values are presented in Table 2 .
Special consideration was given to the size and diversity of the drug set in selecting the dosing and sampling regimen for this study. Based on the number and completeness of the concentration profiles obtained, the regimen employed provided sufficient data for assessment of P-gp impact on
brain exposures for all drugs tested. For 85% of the CNS drugs, concentrations in plasma and brain samples were reportable for at least 3 of the 4 time points collected. In a limited number of cases (N=6) plasma, brain, or CSF concentrations were observed for only 2 of the 4 time points collected:
carisoprodol, ethosuximide, hydrocodone, meprobamate, sertraline, and sulpiride. Sertraline was the only example of a CNS drug for which CSF concentrations were detected at only a single time point in each genotype. Plasma and brain concentrations for all the control drugs were also captured in at least 3 of the 4 time points, although the CSF concentrations were more sporadic. Drug concentrations of amiodarone, loratadine, and ritonavir were not measureable in CSF of KO or WT mice, and were only observed in 2 of the 4 time points for prazosin (WT and KO) and lopermide (WT only).
Representative time courses are presented in Figure 1 as reflective of the diversity in the pharmacokinetic profiles observed across drugs as well as across matrices for individual drugs. As represented by the concentration profiles for zolpidem, most drugs exhibited mono-exponential declines in plasma concentration profiles with brain and CSF concentration profiles tracking in parallel with plasma. In some cases, such as paroxetine, a lag in the brain concentration profile was observed relative to the plasma concentration profile. For all the drugs studied, plasma T max values were observed at the 0.5 hr time point and were consistent between the FVB and mdr1a/1b dose groups, with the exception of lamotrigine and amiodarone for which maximal plasma concentrations were observed at the 1 and 2.5 hr sampling times, respectively.
This article has not been copyedited and formatted. The final version may differ from this version. values between mdr1a/1b and FVB mice. To account for any differences in the systemic exposures resulting from the P-gp genotype, brain and CSF AUC(0→t last ) values were normalized for plasma AUC(0→t last ) and are reported as brain/plasma (B/P) and CSF/plasma (CSF/P) ratios, respectively (Table 4 and 5). In FVB mice, the B/P AUC values for all CNS drugs ranged from 0.060 (9-OH risperidone) to 24 (sertraline) and the CSF/P values ranged from 0.015 (paroxetine) to 1.6 (ethosuximide). A large percentage of CNS drugs, 80% (20 of 25 basic drugs) and 65% (22 of 34 all CNS drugs) demonstrated B/P ratios ≥ 1 in the wild-type mice. With the exception of diazepam, which had a B/P ratio of 2.0, all the neutral CNS drugs had B/P ratios less than unity in FVB mice. The B/P ratios of the metabolites, meprobamate and 9-hydroxyrisperidone, were also determined to be <1 and
were decreased compared to their respective parents, carisoprodol and risperidone.
To determine the effects of the lack of P-gp expression on the brain penetration of CNS drugs in mdr1a/1b mice relative to their WT counterparts, the ratio of KO/WT values for B/P or CSF/P were compared for statistical significance against values of unity or 2-fold. Surprisingly, a majority of the CNS drugs (27 of 34) demonstrated a significant increase in the KO/WT B/P ratios when compared against unity. In most cases these increases were marginal and in fact, only four drugs demonstrated a significant difference in the KO/WT ratio of B/P values when evaluated against a 2-fold increase:
fluvoxamine, metoclopramide, propoxyphene, and risperidone (as well as the active metabolite 9-hydroxyrisperidone). The CNS drugs for which brain concentrations were most dramatically increased in the absence of P-gp were metoclopramide (6.6-fold), risperidone (10-fold), and 9-hydroxyrisperidone (17-fold). CSF concentrations for these drugs also showed marked alterations in P-gp KO mice.
Results for the non-CNS drugs included in the study as controls are presented in Tables 3 and   and 5 . The B/P ratios for all the non-CNS drugs examined were less than unity. Quinidine demonstrated the greatest increase in B/P ratio of any drug in the study when comparing KO to WT mice, 36-fold. Loperamide also demonstrated a significant increase in KO B/P relative to WT mice, 9.3-fold. The brain to plasma ratios of loratadine and verapamil, increased 1.9 and 17-fold, respectively, in KO versus WT mice and were consistent with data reported in the literature from 
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13 similar brain penetration studies conducted in P-gp genetically modified mice (Chen, et al, 2003; Hendrikse et al, 1998 ) . Results with amiodarone demonstrate a 21-fold increase in the B/P ratio of KO mice relative to WT mice indicating that it is a substrate for P-gp. Moderate increases in KO/WT B/P ratios were also observed for prazosin and prednisone, 2.0 and 2.3-fold, respectively. Given the limited CSF data available for the some of the non-CNS drugs, CSF/P values are only reported for loperamide, prazosin, prednisone, quinidine, and verapamil.
Discussion
The potential for P-gp mediated transport poses a specific challenge to the discovery of new CNS agents by virtue of its function as an efflux transporter at the blood-brain barrier. For any agent intended to act in the brain, the success of eliciting a desired response is dependent on passive diffusion (related to the physicochemical properties of the compound) and the relative balance between active uptake and efflux transporters at the blood brain barrier. Development of the mdr1a/1b knockout mouse model has provided a powerful tool for evaluating the effects of P-gp transport on brain and CSF pharmacokinetics for CNS-active agents in intact animals. To understand the prevalence and magnitude of P-gp interactions occurring within this class of therapeutic agents we compared the central exposures of 32-clinically useful CNS drugs (and two active metabolites) across a 5 hour time course in wild-type and mdr1a/1b (-/-, -/-) mice following subcutaneous administration.
The results offer insight not only to the relevance of P-gp transport for CNS drugs, but also to the characteristics of CNS agents with regard to brain to plasma ratios and CSF to plasma ratios.
Brain-to-Plasma and CSF-to-Plasma Ratios: General Considerations. The CNS-active agents evaluated in the mouse did not demonstrate any particular trend regarding B/P ratios. Some B/P ratios for established CNS agents were as low as 0.060 to 0.46, while others were greater than 20. Thus, there is no requirement that CNS drugs achieve some threshold in total B/P ratios, although none exhibited B/P values below that which represents vascular volume in the brain (0.6-1.3 ml/100 gm brain; Dagenais, et al., 2000) .
Our results demonstrate a difference in the brain pharmacokinetics of neutral or weakly acidic CNS drugs compared with basic CNS drugs. Neutral or acidic drugs tended to have lower B/P ratios in wild-type mice. Of the nine CNS drugs in the CNS drug set considered to be "non-basic", eight of them demonstrated B/P ratios equal to or less than 1, lower than those observed for the majority of basic CNS drugs. In contrast, only seven of the basic CNS drugs had B/P ratios < 1 in the wild-type mice, and only 2 of those could be attributed to large P-gp efflux. These results indicate that lower brain partitioning is common among non-basic CNS drugs and may not necessarily be associated with decreased potential for central activity. Lipophilic, weakly basic drugs, being cationic at physiological pH, may associate with phospholipid membranes, which could explain the difference in brain partitioning between weak bases and other molecules.
B/P and CSF/P ratios were not correlated. In the absence of active transport between blood and brain, CSF concentrations should approximate unbound plasma concentrations provided that the drug can penetrate the tissue. Thus, there should be no expectation that CSF and brain concentrations would be correlated, since total brain concentrations are largely driven by non-specific binding of drugs to brain tissue (Maurer, et al., 2004 ).
Brain-to-Plasma and CSF-to-Plasma Ratios: Comparison of P-Glycoprotein Knockout
and Wild-Type Mice. Most of the drugs assessed in this study showed some difference between wild-type and P-gp knockout mice in brain-to plasma or CSF-to-plasma ratios. Thus, it appears that successful CNS agents can still be substrates for P-gp. However, the relative impact of P-gp mediated efflux needs to be balanced with rates of passive diffusion. For in vitro transport studies, Polli et al (2001) categorized drugs with regard to penetrability and active transport. One category was referred to as "non-transported substrates" and included drugs such as chlorpromazine and midazolam. Such drugs appear to be substrates for P-gp but with no readily apparent impact of transport affecting disposition. In comparing B/P ratios in P-gp knockout vs wild-type mice, it appears that many CNS compounds fit into such a category. B/P ratios in knockout mouse are statistically greater than corresponding values in wild-type mice, but the values rarely exceed 2. Such drugs are probably not limited in their capability to elicit central effects despite being substrates of P-gp in vivo. It is noteworthy that B/P and CSF/P ratios in wild-type vs knockout animals were well-correlated but lacking a one-to-one correspondence (Tables 4 and 5 ). This suggests that CSF represents a viable biofluid that can be used to assess the impact of P-gp on CNS exposure.
Consideration of Specific CNS-Active Drugs.
The most interesting results obtained for a centrally active agent were for risperidone. Clearly risperidone is a well-established, clinically useful antipsychotic agent. Yet the data obtained regarding B/P ratios in knockout vs wild-type mice suggests a profound impact of P-gp on the central exposures for risperidone and its active metabolite 9-hydroxyrisperidone. The KO/WT ratio of B/P ratios was 10 for risperidone, with a corresponding value for CSF/plasma of 6.3. Should this same magnitude of efflux impact risperidone disposition in humans, it would be expected that lack of concordance would be apparent between efficacious free plasma concentrations, receptor affinity, and receptor occupancy. However, receptor occupancy, as measured using SPECT for the D 2 receptor ranges, on average, between 50% and 79% for steadystate efficacious doses of risperidone of 2-4 mg/day (Bressan, et al., 2003; Lavalaye, et al., 1999) .
Concentrations associated with these doses range around 10 ng/mL for risperidone and 35 ng/mL for 9-hydroxyrisperidone; correcting for free fraction (0.11 and 0.23, respectively; Thummel and Shen, 2001 ) yields concentrations of approximately 1.1 and 8.1 ng/mL, respectively. The D 2 receptor K i values for risperidone and 9-hydroxyrisperidone are 2.5 and 1.9 ng/mL respectively (6 and 4.5 nM; Schotte, et al., 1996) . Thus, while P-gp could decrease the "receptor-available concentrations" of risperidone and 9-hydroxyrisperidone relative to the free plasma concentration, risperidone remains an effective antipsychotic agent, due to its high potency. This is also consistent with receptor occupancy data gathered in the rat for risperidone in which striatum vs pituitary D 2 receptor occupancy is markedly different (Kapur, et al., 2002) , presumably due to active efflux of risperidone from the brain.
Thus, significant P-gp efflux does not preclude a new drug from being a successful CNS agent, however it can alter the relationship between free plasma concentrations and potency.
Citalopram was previously reported to be a P-gp substrate in vivo, with KO/WT B/P ratio of 3.3 (Uhr and Grauer 2003a), vs our presently reported value of 1.9. In either case, the impact of P-gp on the action of citalopram appears to be minor and likely of little consequence. Other antidepressants (both SSRIs and TCAs) demonstrated statistically significant yet minor differences in brain/plasma ratios between wild-type and knockout animals, which is consistent with other data addressing brain penetration of this class of drugs (Uhr, et al., 2000 (Uhr, et al., , 2003b . Of the antidepressants examined, the impact of P-gp on brain to plasma ratios was less than 2.3-fold but sertraline was the only antidepressant tested that demonstrated no statistically significant difference between wild type and knockout strains.
Of the two benzodiazepines examined, diazepam and midazolam, neither demonstrated a difference in B/P ratios in knockout vs wild-type mice. Midazolam showed a remarkably low B/P ratio, approximately 8-fold lower than diazepam. Midazolam has been claimed to be a P-gp substrate, but with a very high rate of passive diffusion, overall minimal differences were observed in in vitro permeability studied in MDR1 transfected vs non-transfected MDCK cells (Tolle-Sander, et al., 2003) .
Our data suggest that P-gp has no impact on the brain penetration of midazolam.
Pollack and coworkers have demonstrated an impact of P-gp on the action of morphine in rats and mice using modulators of P-gp activity and genetically modified animals (Zong and Pollack, 2000, 2003; Aquilante, et al., 1999; Latrent, et al., 1999; Daganais, et al., 2004) . However, a corresponding impact of P-gp on the action of morphine in humans has not been shown (Skarke, et al., 2003; Drewe, et al., 2000) . Our data shows a minimal impact of P-gp on brain penetration of morphine and was very similar to previously reported findings (Zong and Pollack, 2000) .
Metoclopramide showed a substantial difference in B/P ratio between wild-type and P-gp knockout animals. B/P ratios were greater than unity in both strains, but were nearly 7-fold greater in knockout animals. There is an unclear picture regarding the site of action of metoclopramide as an antiemetic agent as to whether it is central or peripheral. The site of dopiminergic activity of metoclopramide has been claimed to be in the fourth ventricle, which is outside the BBB (Gralla, 1983) , and antiemetic activity has also been ascribed to peripheral cholinergic activity (Singamma and Prabhakara Rao, 1992) . In context to this proposed site of action, it is interesting to note that a less pronounced increase in the CSF/plasma ratio vs. brain/plasma ratio using the P-gp knockout genotype was observed for metoclopramide. In light of our observations, the potential impact of P-gp on metoclopramide potency and CNS side effects in humans warrants further investigation, and a determination of the effect of P-gp inhibition on metoclopramide pharmacokinetic/pharmacodynamic relationships in the clinic may provide valuable insight to the mechanism of action of this agent.
Summary. This report represents the first systematic evaluation of brain penetration of a large number of successful CNS active agents in the P-gp knockout mouse model. It is clear that most drugs, even those targeting the CNS, demonstrate some difference between B/P and CSF/plasma ratios between knockout and wild-type animals. However, differences of 2 to 3-fold or less between brain to plasma ratios between KO and WT animals do not appear to have much impact on the success of drugs as CNS active compounds. Some CNS active drugs even demonstrated substantially greater B/P ratios in KO mice vs WT mice, yet are still successful therapeutic agents (i.e.
risperidone and metoclopramide). It is likely that for such compounds the relationship between free
This article has not been copyedited and formatted. The final version may differ from this version. plasma concentrations, target receptor affinity, and resulting receptor occupancy (and hence effect) demonstrate some discord. Total B/P ratios themselves do not appear to be important in distinguishing CNS drugs, as some agents had ratios of well below unity (e.g. sulpiride, midazolam, zolpidem, etc.) This is consistent with the well-accepted "free drug hypothesis" and information in the accompanying report (Maurer, et al., 2004) since B/P ratios are largely driven by non-specific brain tissue binding which represents drug that is not necessarily available for receptor binding. Finally, CSF appears to be a viable biofluid from which the impact of P-gp on CNS exposure can be addressed.
The extent to which differences in B/P ratios in P-gp knockout vs wild-type mice can be applied to estimating human concentration-response relationships remains undetermined and an area of future research. Limitations of this model likely exist. Since the brain is a complex, multicompartmented organ, there likely exist other distributional aspects of drugs within the brain that cannot be addressed with measurements of total brain concentrations. Also, it has recently been shown that knockout of P-gp in the mouse can result in changes in expression of other transporters (Cisternino, et al., 2004) . Finally, the potential for mouse-human differences in intrinsic activity of their respective P-gp transporters as well as species similarities/differences expression levels at the bloodbrain barrier needs to be explored. This article has not been copyedited and formatted. The final version may differ from this version. 
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